1. Regeneron Pharmaceuticals Inc, Tarrytown, NY (A.D., P.B., G.M., R.P., J.D.O., L.A.L., G.D.Y., G.R.A., A.B., C.P.).
2. Université de Paris, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, INSERM U1148, France (P.G.S.).
3. University of Colorado School of Medicine, Aurora (G.G.S.).
4. Department of Biostatistics and Epidemiology, SUNY Downstate School of Public Health, Brooklyn, NY (M.S.).
5. Department of Medical Sciences, Cardiology, Uppsala University, Sweden (E.H.).
6. Cardiovascular Program-ICCC, CiberCV, IR-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (L.B.).
7. Endocrinology Metabolism Division, Pitie–Salpetriere University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France (M.J.C.).
8. Université de Paris, INSERM U1148 and Genetics Department, APHP-Hospital Bichat-Claude Bernard, France (C.B.).
9. Sulpizio Cardiovascular Center, Division of Cardiovascular Medicine, University of California San Diego, La Jolla (S.T.).
10. Irving Institute for Clinical and Translational Research, Columbia University, New York (H.N.G.).
11. Sanofi Aventis Deutschland GmbH, Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses, Frankfurt, Germany (S.H.).